BibTex format
@article{Quraishi:2024:ecco-jcc/jjae189,
author = {Quraishi, MN and Cheesbrough, J and Rimmer, P and Mullish, BH and Sharma, N and Efstathiou, E and Acharjee, A and Gkoutus, G and Patel, A and Marchesi, JR and Camuzeaux, S and Chappell, K and Valdivia-Garcia, MA and Ferguson, J and Brookes, M and Walmsley, M and Rossiter, A and van, Schaik W and McInnes, RS and Cooney, R and Trauner, M and Beggs, A and Iqbal, T and Trivedi, PJ},
doi = {ecco-jcc/jjae189},
journal = {Journal of Crohn's and Colitis},
title = {Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures},
url = {http://dx.doi.org/10.1093/ecco-jcc/jjae189},
year = {2024}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV) treatment, in primary sclerosing cholangitis associated inflammatory bowel disease (PSC-IBD); NCT05376228.</jats:p> </jats:sec> <jats:sec> <jats:title>Method</jats:title> <jats:p>Fifteen patients with PSC and active colitis (median faecal calprotectin 459µg/g; median total Mayo score 5) were treated with OV (125mg QID) for 4 weeks and followed-up for a further 4 weeks of treatment withdrawal (8 weeks, end-of-study). Colonic biopsies were obtained at baseline and week 4. Clinical assessments, and serum and stool samples (metagenomics, metatranscriptomics and metabolomics) were collected at weeks 0, 2, 4 and 8. The primary efficacy outcome measure was induction of clinical remission.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>OV resulted in clinical remission in 12/15 patients and significant reductions in faecal calprotectin. OV was associated with reduced abundances of Lachnospiraceae, genera Blautia and Bacteroides; and enrichment of Enterobacteriaceae, and genera Veillonella, Akkermansia and Escherichia. OV treatment was associated with downregulation of multiple metatranscriptomic pathways (including short chain fatty acid [SCFA] metabolism and bile acid [BA] biotransformation), along with host genes and multiple pathways involved in inflammatory responses and antimicrobial defence; and an upregulation of genes associated with extracellular matrix repair. OV use resulted in loss of specific faecal SCFAs and secondary BAs, including
AU - Quraishi,MN
AU - Cheesbrough,J
AU - Rimmer,P
AU - Mullish,BH
AU - Sharma,N
AU - Efstathiou,E
AU - Acharjee,A
AU - Gkoutus,G
AU - Patel,A
AU - Marchesi,JR
AU - Camuzeaux,S
AU - Chappell,K
AU - Valdivia-Garcia,MA
AU - Ferguson,J
AU - Brookes,M
AU - Walmsley,M
AU - Rossiter,A
AU - van,Schaik W
AU - McInnes,RS
AU - Cooney,R
AU - Trauner,M
AU - Beggs,A
AU - Iqbal,T
AU - Trivedi,PJ
DO - ecco-jcc/jjae189
PY - 2024///
SN - 1873-9946
TI - Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures
T2 - Journal of Crohn's and Colitis
UR - http://dx.doi.org/10.1093/ecco-jcc/jjae189
UR - https://doi.org/10.1093/ecco-jcc/jjae189
UR - http://hdl.handle.net/10044/1/116113
ER -